Coordintated by Amyndas Biopharmaceuticals (partner 8), in collaboration with partners 1a, 6, and 8.
The objective of WP8 is to bring Compstatin from a preclinical drug candidate to the stage were it could be tested in a clinical trial with the indication of ABO-incompatible kidney transplantation. This will include GMP production of Compstatin, preclinical safety and toxicology testing, IND application, phase 1 clinical trial and phase 2a clinical trial with the indication of ABO-incompatible kidney transplantation.